Morepen Laboratories Share Price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 50,63,581 shares,. Its Average Traded Price (ATP) is ₹118.45, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 2 @ ₹123.54.
Morepen Laboratories has an upper circuit limit of ₹129.71 and a lower circuit limit of ₹117.37. The total value traded stands at ₹59.98 CR, and the delivery percentage for the day is 0%.
The stock is currently traded with a market lot size of 1. Morepen Laboratories also offers a dividend yield of 0.16%.
Morepen Laboratories Share Price Chart
Morepen Laboratories Share Key Metrics
Volume
50.64 L
Market Cap
6769.42 CR
LTQ@LTP
2@123.54
ATP
118.45
Var Margin
100 %
Circuit Range
117.37-129.71
Delivery %
0 %
Value
59.98 CR
ASM/GSM
No
Market Lot
1
Morepen Laboratories Resistance and Support
Pivot 116.35
Resistance
First Resistance
122.5
Second Resistance
127.34
Third Resistance
133.49
Support
First Support
111.51
Second Support
105.36
Third Support
100.52
Morepen Laboratories Shareholding Pattern
View More- 2016-17
- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Morepen Laboratories News
Morepen Laboratories Ltd - 500288 - Board Meeting Intimation for Q-2 FY27 Financial Results
Morepen Laboratories announced a board meeting scheduled for 27 Oct 2026. The board will consider and approve the financial results for the quarter ended 30 Sep 2026.
Oct 22 2026 18:31:13
Morepen Laboratories Ltd - 500288 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Morepen Laboratories received a favorable judgment from the High Court of Himachal Pradesh, quashing a show cause notice for the recovery of Rs.117.94 crores in excess GST refunds. The writ petition was disposed of in favor of the company.
Oct 14 2026 18:14:14
Morepen Laboratories Ltd - 500288 - Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)
Morepen Laboratories submitted its first Abbreviated New Drug Application (ANDA) to the U.S. FDA for Sitagliptin Tablets USP. This strengthens the company's integrated CDMO capabilities and expands its finished dosage development into regulated markets.
Sep 28 2026 08:53:27
Morepen Laboratories Management
| Name | Position |
|---|---|
| Sushil Suri | Chairman & Managing Director |
| Sanjay Suri | Whole Time Director |
Morepen Laboratories Similar Stocks
Thyrocare Technologies Ltd.
463.15
-8.95 (1.90%)
Sanofi India Ltd.
2772.80
-58.30 (2.06%)
Bliss GVS Pharma Ltd.
623.35
-19.35 (3.01%)
Kovai Medical Center & Hospital Ltd.
5757.50
-49.00 (0.84%)
Nephrocare Health Services Ltd.
596.45
-5.95 (0.99%)
Senores Pharmaceuticals Ltd.
1215.30
12.70 (1.06%)
Innova Captab Ltd.
987.30
-9.20 (0.92%)
FDC Ltd.
338.70
-1.75 (0.51%)
Orchid Pharma Ltd.
823.30
-52.25 (5.97%)
Morepen Laboratories FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in MOREPENLAB
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade
+ Free 1st Year AMC
Or Download Choice FinX App
Invest in MOREPENLAB
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade